Sanofi's Financial Triumph in Q2 2025

Sanofi SA has unveiled its financial results for the second quarter of fiscal year 2025, showcasing a remarkable 6% year-over-year increase in net sales, reaching an impressive €10 billion. When adjusted for constant exchange rates (CER), the growth further accelerates to 10.1%.

Profitability and Earnings Highlights

The company's net income, under the International Financial Reporting Standards (IFRS), witnessed an extraordinary surge of 253% annually, amounting to €4 billion. IFRS earnings per share (EPS) also saw a significant jump of 264%, landing at €3.24. However, it wasn't all upward trends, as business net income experienced a slight decline of 0.6% to €2 billion, though it showed a 5.1% increase at CER. Business EPS, on the other hand, rose by 1.9% (8.3% at CER) to €1.59.

Gross Profit and Future Outlook

Sanofi's gross profit in the reported quarter advanced by 8% (12.4% at CER), totaling €7.75 billion. CEO Paul Hudson expressed optimism, stating, "Based on strong sales performance in H1, we are refining our 2025 sales guidance to the upper end of our previous range. We also confirm our guidance of a strong business EPS rebound, now inclusive of all expenses from newly acquired businesses."